

BRAND INSTITUTE IS PROUD TO HAVE PARTNERED  
ON 30 FDA-APPROVED BIOSIMILAR BRAND NAMES

 <b>Abrilada™</b> (adalimumab-afzb) Injection	 <b>AMJEVITA™</b> (adalimumab-atto) Injection 40mg/0.8mL & 20mg/0.4mL	 <b>AVSOLA®</b> (infliximab-axxq) For Injection 100mg/vial
 <b>Byooviz™</b> ranibizumab-nuna	 <b>CIMERLI™</b> (ranibizumab-eqrn) injection	 <b>Erelzi™</b> (etanercept-szsz)
 <b>Fylnetra®</b> (pegfilgrastim-pbbk)	<b>HADLIMA™</b> (adalimumab-bwwd) injection	 <b>Herzuma®</b> (trastuzumab-pkrb) For Injection • 420 mg/vial • 150 mg/vial
 <b>Hulio®</b> (adalimumab-fkjp) injection	 <b>Hyrimoz®</b> adalimumab-adaz	 <b>Idacio®</b> adalimumab-aacf
<b>IXIFI</b> (infliximab-qbtx)	 <b>KANJINTI®</b> (trastuzumab-anns) For Injection 420mg/vial multiple dose	 <b>MVASI®</b> (bevacizumab-awwb) Injection 100mg/vial & 400mg/vial
<b>INJECTION</b> <b>Nivestym®</b> filgrastim-aafi	<b>INJECTION</b> <b>Nyvepria™</b> pegfilgrastim-apgf	 <b>Ontruzant®</b> trastuzumab-dttb for injection, for intravenous use 21 mg/mL
<b>Releuko®</b> (filgrastim-ayow) Injection	<b>RENFLEXIS®</b> (infliximab-abda) for injection, for intravenous use 100 mg	<b>INJECTION</b> <b>Retacrit®</b> epoetin alfa-epbx
<b>INJECTION</b> <b>Ruxience®</b> rituximab-pvvr	<b>INJECTION</b> <b>Trazimera®</b> trastuzumab-qyyp	 <b>Truxima®</b> (rituximab-abbs) Injection for intravenous use 500 mg/50 mL • 100 mg/10 mL
 <b>UDENYCA®</b> pegfilgrastim-cbqv	 <b>Vegzelma®</b> bevacizumab-adcd Injection 100mg/vial & 400mg/vial	 <b>Yuflyma®</b> adalimumab-aaty
 <b>YUSIMRY™</b> (adalimumab-aqvh) Injection	 <b>ZIEXTENZO®</b> (pegfilgrastim-bmez)	<b>INJECTION</b> <b>Zirabev®</b> bevacizumab-bvzr

**About Brand Institute and our wholly owned regulatory subsidiary, Drug Safety Institute**

Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 4,000 marketed healthcare brand names, 1,300 USAN/INN nonproprietary names for 1,200 clients. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers. Drug Safety Institute is composed of former naming regulatory officials from global government health agencies, including Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), American Medical Association (AMA), and the World Health Organization (WHO).

[BI\_SIGNATURE]